No added val­ue for a drug's new in­di­ca­tion? Price should ad­just, re­searchers say

As more fol­low-on treat­ments with in­cre­men­tal im­prove­ments win ap­proval in the US and Eu­rope, new re­search pub­lished yes­ter­day notes that few­er than half of the first in­di­ca­tion ap­provals for new drugs in the US and Eu­rope were rat­ed as hav­ing high ther­a­peu­tic val­ue.

Ther­a­peu­tic val­ue was de­ter­mined in the study by rat­ings for first and sup­ple­men­tal in­di­ca­tions made by France’s Min­istry of Health and Ger­many’s Fed­er­al Joint Com­mit­tee, based on eval­u­a­tions and re-eval­u­a­tions of drugs con­duct­ed and pub­lished as of De­cem­ber 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER